3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Endometrial Neoplasms
10
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer (LARC)
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Mouth Neoplasms
1
Interventions
Pemetrexed
22
Cisplatin
20
Nivolumab
8
Gemcitabine
7
Carboplatin
7
durvalumab
5
Ipilimumab
5
Bevacizumab
5
pembrolizumab
4
Radiotherapy, Intensity-Modulated
4
tremelimumab
3
niraparib
3
Oxaliplatin
3
Drug Therapy
3
Cyclophosphamide
3
Cerebral Decortication
3
Blood Specimen Collection
3
sargramostim
2
Thoracoscopy
2
Surveys and Questionnaires
2
Sorafenib
2
Radiosurgery
2
Magnesium Sulfate
2
Leucovorin
2
Imatinib Mesylate
2
Hyperthermic Intraperitoneal Chemotherapy
2
Doxorubicin
2
Dexamethasone
2
tislelizumab
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma
×
dostarlimab
×
Clear all
NCT04940637
2023-05-12
UNITO-001
University of Turin, Italy
Phase 2
Unknown
70 enrolled